Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart. Issue 1 (3rd January 2021)

• Record Type: Journal Article
• Authors: Shearer, Jeffry D.; Henning, Lisa; Sanford, Daniel C.; Li, Na; Skiadopoulos, Mario H.; Reece, Joshua J.; Ionin, Boris; Savransky, Vladimir
• Is Part Of: Vaccine. Volume 39:Issue 1(2021)
• Page Start: 1
• Page End: 5
• Publication Date: 2021-01-03
• Subjects: Animal rule -- Correlates of protection -- TNA threshold -- Anthrax vaccine -- CPG 7909 adjuvant -- Guinea pig -- Cynomolgus macaque; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.10.095
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for post-exposure prophylaxis (PEP) against inhalational anthrax. In clinical studies, two vaccinations with AV7909 administered either two or four weeks apart induced an enhanced immune response compared to BioThrax® (Anthrax Vaccine Adsorbed) (AVA). Anthrax toxin-neutralizing antibody (TNA) levels on Day 70 following initial vaccination that were associated with protection of animals exposed to inhalational anthrax were previously reported for the 0, 4-week AV7909 vaccination regimen. The current study shows that a 0, 2-week AV7909 vaccination regimen protected guinea pigs (GPs) and nonhuman primates (NHPs) against a lethal inhalational anthrax challenge on Days 28 and 70 after the first immunization. An earlier induction of protective TNA levels using a 0, 2-week AV7909 vaccination regimen may provide benefit over the currently approved AVA PEP 0, 2, and 4-week vaccination regimen.